OUR DEVELOPMENT PIPELINE
Discovery in motion.Progress with purpose. Two programmes advancing from discovery towards lead optimisation. Each next step builds on the work already completed.
AI · BIOINFORMATICS · EXPERIMENTAL SCIENCE Programme update · November 2026
HOW TO READ THE PIPELINE Completed Next planned step Future development01 / SMALL MOLECULES
Small-molecule programme ✓ Candidates selectedFrom target biology to selected compounds. Target identification, target validation, library screening and candidate selection are complete.
✓ Target identification Completed ✓ Target validation Completed ✓ Library screening Completed ✓ Candidate selection Completed 05 Lead optimisation Next 06 Preclinical development Future 07 Clinical development Future NEXT MILESTONE / LEAD OPTIMISATION
Refine the selected candidates. Lead optimisation is the next planned stage, building on the compounds selected through screening.
Discuss this programme ↗ 02 / ANTIMICROBIAL PEPTIDES
AMR peptide programme ✓ Leads selectedAdvancing peptides against antimicrobial resistance. Peptide design and screening are complete, and leads have been selected for further development.
JOINT DEVELOPMENT & OWNERSHIP
This programme is co-developed and co-owned by FremtidBio AS and ModelMole .
✓ Peptide design Completed ✓ Screening Completed ✓ Lead selection Completed 04 Lead optimisation Next 05 Preclinical development Future 06 Clinical development Future NEXT MILESTONE / LEAD OPTIMISATION
Build on the selected peptide leads. The planned next step is lead optimisation, followed by further evaluation of the refined leads.
Discuss this programme ↗ “Completed” refers to the discovery stages shown. Lead optimisation is planned; future preclinical and clinical stages are prospective and depend on results and development decisions. Research candidates are not approved medicines.
THE NEXT CHAPTER
Advance the next stage with us. We welcome research and development partnerships to help advance our selected compounds and peptide leads.
Explore a partnership ↗